✦ LIBER ✦

A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia

✍ Scribed by Anger, B. ;Porzsolt, F. ;Leichtle, R. ;Heinze, B. ;Bartram, C. ;Heimpel, H.

Publisher: Springer-Verlag
Year: 1989
Weight: 337 KB
Volume: 58
Category: Article
ISSN: 1432-0584
DOI: 10.1007/bf00320165

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study alternating alpha-2a-in

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia

✍ M. Talpaz; R. Kurzrock; H. Kantarjian; J. Rothberg; S. Saks; L. Evans; J. U. Gut 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 549 KB

Randomized study on the treatment of chr

Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha

✍ Hehlmann, R. ;Anger, B. ;Messerer, D. ;Zankovich, R. ;Bergmann, L. ;Kolb, H. J. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 453 KB

A phase I study of subcutaneous recombin

A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a

✍ Mark J. Ratain; Edwin R. Priest; Linda Janisch; Nicholas J. Vogelzang 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 2 views

Background. Both recombinant in1 erferon alfa and interleukin-2 (IL-2) have been shown to lave some activity as single agents in metastatic renal cj !I1 cancer (RCC), although their activity is minimal in mo -e common solid tumors. Recent preclinical studies hav ? suggested that the combination of t

Interferon alpha-2c therapy of patients

Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study

✍ J. Thaler; G. Gastl; T. Fluckinger; D. Niederwieser; H. Huber; H. Seewann; H. Si 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 228 KB

Recombinant interferon alfa-2a in advanc

Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic

✍ G. R. C. McLeod; D. B. Thomson; P. Hersey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

A Phase II trial of 5-fluorouracil and r

A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma

✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 3 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do